Antifungal drug developer Scynexis's Q3 net loss widens

Scynexis

05/11/2025 22:53

Overview

Scynexis Q3 2025 net loss widens to $8.6 mln

Company receives $24.8 mln one-time payment from GSK, extending cash runway over two years

Outlook

Scynexis expects up to $146 mln in annual net sales milestones from BREXAFEMME relaunch

Scynexis's cash runway extends over two years, supporting SCY-247 development

Result Drivers

GSK PAYMENT - Scynexis received a one-time payment of $24.8 mln from GSK, resolving a disagreement over the Phase 3 MARIO study

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$334,000
Q3 Net Income
-$8.59 mln
Q3 Basic EPS
-$0.17
Q3 Operating Expenses
$8.74 mln
Q3 Pretax Profit
-$8.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for SCYNEXIS Inc is $4.00, about 84.2% above its November 4 closing price of $0.63

Press Release: ID:nGNX84CtD5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)